Business Standard

Saturday, December 21, 2024 | 09:12 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US

These injections will help control high blood sugar in adult and pediatric patients with type-1 diabetes and adults with type-2

Biocon Biologics, Serum Institute Life Sciences enter strategic alliance
Premium

Deepsekhar Choudhury Bengaluru
Biocon Biologics and Viatris on Tuesday launched their interchangeable insulin biosimilar in the US market. The launch includes Semglee, which is a branded product, Insulin Glargine, which is an unbranded injection.

These injections will aid control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. The currently marketed non-interchangeable Semglee is anticipated to be phased out by the end of the 2021 calendar year.

Shreehas Tambe, deputy CEO of Biocon Biologics, said: “This is indeed a landmark event and along with the recent formulary listings, we believe it will allow us

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in